FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 231 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer September 13, 2022 FDA Approves Injectable Nivolumab, an Alternative to IV Infusion February 19, 2025 Cancer Won’t Wait: “I prayed she would see her daughter start... October 11, 2021 Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 Load more HOT NEWS New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free Liquid Biopsies on the Horizon for Children with Solid Cancers Breast Cancer Patient Does Head-Shaving Photo Shoot in Hopes of Inspiring... Fostering Black leadership in cancer research
